The applications of the C7R construct to GD2-CAR T cells and EphA2-CAR T cells effectively targeting metastatic neuroblastoma and orthotopic GBM in animal models, respectively, are particularly attractive since these approaches do not necessitate an external administration of IL-7 with potential debilitating cytotoxicity [18,19]. This evidence concerns the gene IL7 and glioblastoma.